•  
  •  
  •  
  •  

2025-10-17 07:35:49

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Sprayking Ltd Q2 FY2026 consolidated PAT at Rs. 4.10 crore
  • Waaree Energies Ltd Q2FY26 consolidated net profit increases to Rs. 842.55 crores
  • Rajesh Power Services Ltd bags orders worth Rs. 921.89 crore from UGVCL
  • Novelix Pharmaceuticals Ltd signs Technology Transfer agreement GMBU e.V., Germany for Large-Scale of Astaxanthin
  • Central Bank of India announces Co-Lending Partnership with Godrej Housing Finance Ltd

Keywords Selected:  Biocon

Research

  • Biocon Limited - Generics & research grow; biosimilar stagnates - ICICI Securities
  • Q4FY22 Result Update – Biocon Ltd - ICICI Direct
  • Biocon - Q4FY22 First Cut - ICICI Direct
  • Q3FY22 Result Update - Biocon Ltd - ICICI Direct
  • Q2FY22 Result Update - Biocon Ltd - ICICI Direct

Stock Report

  • Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine
  • Biocon Limited updates on GMP inspection by USFDA at its Cranbury, New Jersey facility
  • Biocon Pharma Ltd in partnership with Carnegie Pharmaceuticals LLC receives USFDA tentative approval for Rifaximin Tablets
  • Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
  • Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey
  • U.S. FDA Completes Inspection at Biocon Biologics' Facility at Biocon Campus, Bengaluru, India
  • Biocon Foundation and IISc Commemorate World Head & Neck Cancer Day
  • Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™
  • Biocon Biologics receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars
  • Biocon Biologics expands Insulin Access in Malaysia
  • Biocon Biologics receives Health Canada approval for Yesafili™
  • Biocon Biologics Collaborates with National Cancer Society Malaysia
  • Biocon Limited gets approval for diabetes drug Liraglutide in India
  • Biocon Biologics and Yoshindo expand access to Ustekinumab Biosimilar in Japan
  • Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives
  • Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe
  • Biocon Biologics secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
  • Biocon Biologics announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
  • Biocon Biologics and Civica, Inc. collaborate to expand Insulin Aspart access in the United States
  • Biocon Limited launches its Glucagon-like peptide-1 (GLP -1), Liraglutide, in the United Kingdom
  • Biocon Biologics Launches Yesintekâ„¢ Biosimilar to Stelara® in the United States
  • European Commission approves Biocon Biologics' Ustekinumab Biosimilar
  • EMA's CHMP recommends approval of Biocon Biologics' YESINTEK®, biosimilar to J&J's Stelara®
  • Kiran Mazumdar-Shaw Honored by ISQ with 'Jamsetji Tata Award' for Pioneering Biosciences Movement in India

Latest Post

  • Sprayking Ltd Q2 FY2026 consolidated PAT at Rs. 4.10 crore
  • Waaree Energies Ltd Q2FY26 consolidated net profit increases to Rs. 842.55 crores
  • Rajesh Power Services Ltd bags orders worth Rs. 921.89 crore from UGVCL
  • Novelix Pharmaceuticals Ltd signs Technology Transfer agreement GMBU e.V., Germany for Large-Scale of Astaxanthin
  • Central Bank of India announces Co-Lending Partnership with Godrej Housing Finance Ltd


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024